Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
7,923,892
-
Share change
-
-1,000,482
-
Total reported value
-
$12,204,032
-
Put/Call ratio
-
121%
-
Price per share
-
$1.54
-
Number of holders
-
48
-
Value change
-
-$1,958,723
-
Number of buys
-
18
-
Number of sells
-
24
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2022
As of 30 Sep 2022,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,923,892 shares.
The largest 10 holders included
VANGUARD GROUP INC, Artal Group S.A., BlackRock Inc., Laurion Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, DEUTSCHE BANK AG\, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and CITADEL ADVISORS LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.